Analysts predict InterMune’s drug Esbriet, newly approved for a fatal lung disease called idiopathic pulmonary fibrosis, can exceed $1 billion in peak sales. With marketing limited to the EU and little proof the drug slows disease progression, however, blockbuster status remains uncertain: http://www.bnet.com/blog/sec-filings/intermune-8217s-new-lung-disease-drug-doesn-8217t-deserve-its-hype/785
